In vitro evaluation of optimized liposomes for delivery of small interfering RNA

Journal of Liposome Research

Volumn 24, Issue 4, 2014, Pages 270-279

  Yang, Tianzhi ^a   Bantegui, Tracy ^a   Pike, Kaitlynn ^a   Bloom, Raymond ^a   Phipps, Roger ^a   Bai, Shuhua ^a  

^a HUSSON UNIVERSITY   (United States)

Author keywords

Cancer therapy; Cationic liposome; RNA interference; Small interfering RNA; Vascular endothelial growth factor

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; FLUORESCENT DYE; LIPOSOME; MACROGOL 2000; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; POLYELECTROLYTE; SMALL INTERFERING RNA; VASCULOTROPIN; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGAR GEL ELECTROPHORESIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CANCER CELL LINE; LUNG CANCER CELL LINE; PARTICLE SIZE; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; SCANNING ELECTRON MICROSCOPY; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ZETA POTENTIAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; GENE SILENCING; GENETICS; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; GENE SILENCING; HUMANS; LIPOSOMES; NEOPLASM PROTEINS; PARTICLE SIZE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911463398     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2014.907306     Document Type: Article

References (31)

1. Abu Lila AS, Ishida T, Kiwada H. (2009). Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv 6:1297-309.
2. Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36-48.
3. Bai S, Ahsan F. (2010). Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. J Pharm Sci 99:4554-64.
4. Bai S, Gupta V, Ahsan F. (2009). Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. Eur J Pharm Sci 38:165-71.
5. Bai S, Yang T, Abbruscato TJ, Ahsan F. (2008). Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. J Pharm Sci 97:1165-78.
6. Chen Y, Sen J, Bathula SR, et al. (2009). Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm 6:696-705.
7. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443-53.
8. Ewert KK, Zidovska A, Ahmad A, et al. (2010). Cationic liposomenucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem 296: 191-226.
9. Filion MC, Phillips NC. (1997). Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329:345-56.
10. Gomes-da-Silva LC, Fonseca NA, Moura V, et al. (2012). Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 45:1163-71.
11. Hobel S, Koburger I, John M, et al. (2010). Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 12:287-300.
12. Hong YJ, Pyo CG, Kim JC. (2010). Liposomes incorporating hydrophobically modified silk fibroin: pH-dependent release. Int J Biol Macromol 47:635-9.
13. Kanasty R, Dorkin JR, Vegas A, Anderson D. (2013). Delivery materials for siRNA therapeutics. Nat Mater 12:967-77.
14. Kim SH, Jeong JH, Lee SH, et al. (2006). PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 116:123-9.
15. Kubowicz P, Zelaszczyk D, Pekala E. (2013). RNAi in clinical studies. Curr Med Chem 20:1801-16.
16. Mikhaylova M, Stasinopoulos I, Kato Y, et al. (2009). Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther 16:217-26.
17. Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283-318.
18. Mu C, Dave N, Hu J, et al. (2013). Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. J Microencapsul 30:701-8.
19. Ni X, Castanares M, Mukherjee A, Lupold SE. (2011). Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18:4206-14.
20. Rapisarda A, Melillo G. (2012). Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 114:237-67.
21. Schiffelers RM, Ansari A, Xu J, et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149-59.
22. Schroeder A, Levins CG, Cortez C, et al. (2010). Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267:9-21.
23. Shibuya M. (2011). Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for antiand pro-angiogenic therapies. Genes Cancer 2:1097-105.
24. Sitohy B, Nagy JA, Dvorak HF. (2012). Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72:1909-14.
25. Takahashi S. (2011). Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 34:1785-8.
26. Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-60.
27. Van de Water FM, Boerman OC, Wouterse AC, et al. (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34:1393-7.
28. Whitehead KA, Langer R, Anderson DG. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-38.
29. Yang S, Chen Y, Ahmadie R, Ho EA. (2013). Advancements in the field of intravaginal siRNA delivery. J Control Release 167:29-39.
30. Yang T, Nyiawung D, Silber A, et al. (2012). Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin. AAPS PharmSciTech 13: 1309-18.
31. Yuan X, Shah BA, Kotadia NK, et al. (2010). The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 27:1285-95.